Clinical Trials
7
Active:2
Completed:4
Trial Phases
3 Phases
Phase 1:2
Phase 2:3
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (42.9%)Phase 1
2 (28.6%)Phase 3
2 (28.6%)Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.
Phase 1
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: LNK01004 ointment 0.3%Drug: LNK01004 ointment 1.0%Drug: LNK01004 ointment 1.5%Drug: Vehicle BID
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Lynk Pharmaceuticals Co., Ltd
- Target Recruit Count
- 28
- Registration Number
- NCT06553287
- Locations
- 🇨🇳
Hospital for skin diseases, Institute of Dermatology, Chinese Academy of Medical Sciences., Nanjing, China
A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Lynk Pharmaceuticals Co., Ltd
- Target Recruit Count
- 354
- Registration Number
- NCT06277245
- Locations
- 🇨🇳
Dermatological Hospital of Southern Medical University, Guangzhou, China
A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Lynk Pharmaceuticals Co., Ltd
- Target Recruit Count
- 430
- Registration Number
- NCT06276998
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: LNK01001 Dose BDrug: LNK01001 Dose ADrug: placebo
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Lynk Pharmaceuticals Co., Ltd
- Target Recruit Count
- 156
- Registration Number
- NCT06099535
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
A Study of LNK01001 Capsule in Patients With Ankylosing Spondylitis
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Lynk Pharmaceuticals Co., Ltd
- Target Recruit Count
- 177
- Registration Number
- NCT06085534
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
- Prev
- 1
- 2
- Next
News
No news found